Given the remarkable therapeutic efficacy we observed with the TRAIL–CDK9i combination in various models of hard-to-treat cancers, one may envisage that this treatment combination may become widely applicable in cancer therapy, including in the treatment of KRAS-mutated cancers. This evidence concerns the gene TNFSF10 and cancer.